Biotech News

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

PMV Pharmaceuticals (PMVP)PMV Pharmaceuticals2026-02-26 13:00 ESTClinical readout

PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the Phase 1, first-in-human

Related news

IMTXImmatics2026-05-31 13:00 EST

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

EXELExelixis2026-05-30 14:00 EST

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

COGTCogent Biosciences2026-06-30 12:00 EST

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

LYELLyell Immunopharma2026-06-04 20:05 EST

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

COGTCogent Biosciences2026-06-12 12:00 EST

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

View all latest news

PMV Pharmaceuticals

Mutant p53 Precision Oncology PMV Pharmaceuticals develops small molecules that restore activity to specific mutant forms of the tumor suppressor p53. Rezatapopt Rezatapopt selectively binds the TP53 Y220C mutant and is designed to restore wild-type p53 structure and tumor-suppressor function. Ovarian Cancer Lead Indication The PYNNACLE...

Recent company news

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-04-22 12:00 EST

PMV Pharmaceuticals Announces Board Chair Transition

PMVPPMV Pharmaceuticals2026-03-06 13:00 EST

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-02-26 13:00 EST

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

PMVPPMV Pharmaceuticals2025-11-12 13:01 EST

PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

Stock data

Close: 1.18 USD
Market cap: 62.93M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States